These studies highlight the significant benefits of GLP-1 receptor agonists in improving glycemic control and lowering HbA1c levels in patients with type 2 diabetes, offering a robust comparison with other antidiabetic agents. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.